Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

European News

Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation

New analysis demonstrates that insulin-requiring diabetes increases the risk of stroke or systemic embolism in patients with atrial fibrillation

Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA®▼ (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE

Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily LIXIANA®▼ (edoxaban) in Patients with Non-valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016

World Stroke Day 2016: Research reveals delayed diagnosis leaves atrial fibrillation patients at major stroke risk

Daiichi Sankyo announces new data to be presented at the ISPOR EU Congress 2016 analysing the safety, efficacy and cost-effectiveness of LIXIANA®▼ (edoxaban)

Daiichi Sankyo Announces First Patient Enrolled in Phase 3 QuANTUM-First Trial Investigating Quizartinib in Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia

New analysis shows maintained efficacy and safety of LIXIANA®▼ (edoxaban) in patients with acute VTE requiring a reduced dose based on clinical criteria

Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate

Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management